Drugs / Purysis
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT05832281 Comparator | Nov 2023 → Aug 2025 | HIV infectious disease, alexithymia | University of California, San Diego | Terminated | No outcome recorded Stop: Business |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Purysis | “For one week they will titrate up to the maintenance dose of 600 mg/day of Purysis, a synthetic, liquid form of CBD, which they will continue for 4 weeks.” NCT05832281 ↗ |
| Known as | CBD | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05832281 ↗ |